Ligand Pharmaceuticals Inc
NASDAQ:LGND

Watchlist Manager
Ligand Pharmaceuticals Inc Logo
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Watchlist
Price: 116.65 USD 1.75% Market Closed
Market Cap: 2.2B USD
Have any thoughts about
Ligand Pharmaceuticals Inc?
Write Note

Ligand Pharmaceuticals Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ligand Pharmaceuticals Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
Ligand Pharmaceuticals Inc
NASDAQ:LGND
Other Non-Cash Items
$2.3m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
Abbvie Inc
NYSE:ABBV
Other Non-Cash Items
$7B
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
19%
Gilead Sciences Inc
NASDAQ:GILD
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Non-Cash Items
-$419m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Non-Cash Items
$742.4m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Non-Cash Items
$480.1m
CAGR 3-Years
24%
CAGR 5-Years
-6%
CAGR 10-Years
4%
No Stocks Found

Ligand Pharmaceuticals Inc
Glance View

Market Cap
2.2B USD
Industry
Biotechnology

In the bustling world of pharmaceuticals, Ligand Pharmaceuticals Inc. carves a distinct niche for itself as a company that thrives not on direct consumer market engagements but through the engines of innovation and strategic collaboration. Founded in 1987, Ligand has developed a business model centered around drug discovery and development technologies, as well as licensing these advancements to major pharmaceutical partners. Rather than manufacturing products directly for the consumer, Ligand's prowess lies in its proprietary technology platforms, such as Captisol, and its ability to monetize its intellectual properties through alliances. This allows Ligand to fuel a diverse pipeline of partnered products without bearing the risks and costs typically associated with late-stage drug development and commercialization. The company's financial ecosystem is further enriched by royalties, milestone payments, and licensing fees derived from over a hundred medications it has helped bring to market through its partnerships. By providing the technological backbone for novel therapies used in treating cancer, osteoporosis, fungal infections, and more, Ligand benefits financially when its partners succeed in commercializing drugs. This symbiotic model not only maximizes research and development efficiencies for Ligand but also positions the company as a crucial player in the value chain of the pharmaceutical industry. Their approach effectively balances innovation with financial prudence, enabling Ligand to focus on expanding its platform capabilities while diversifying its revenue streams.

LGND Intrinsic Value
82.48 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Ligand Pharmaceuticals Inc's Other Non-Cash Items?
Other Non-Cash Items
2.3m USD

Based on the financial report for Sep 30, 2024, Ligand Pharmaceuticals Inc's Other Non-Cash Items amounts to 2.3m USD.

What is Ligand Pharmaceuticals Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 10Y
-19%

The average annual Other Non-Cash Items growth rates for Ligand Pharmaceuticals Inc have been -27% over the past three years , and -19% over the past ten years .

Back to Top